Navigation Links
Chemo Patients Pose Potential Public Health Risk
Date:9/19/2013

NEWPORT, R.I., Sept. 19, 2013 /PRNewswire-iReach/ -- In its second edition of "Safe Management of Wastes from Health-Care Activities," released in August, the World Health Organization (WHO) singled out contact with residual amounts of chemotherapy drugs as a significant risk requiring collection, containment and proper disposal in order to avoid exposure "through contact with body fluids and secretions [urine, feces and vomit] of patients undergoing chemotherapy."

Genotoxic/cytotoxic compounds, most commonly found in chemotherapy drugs, work by either mutating or killing cells. Unlike poisons, which can be safe when exposure is limited to tiny amounts, genotoxins/cytotoxins act more like "chemical germs," where even minimal exposure can cause a devastating chain reaction. The risk from contact to an otherwise healthy person is especially heightened when there is a significant amount of cell development happening — for example, among children and women of childbearing age.

According to the WHO report, any wastes produced by these patients within 48 hours of drug administration, and in some cases for up to a week, should be considered genotoxic.

Despite the otherwise well-regulated and well-managed handling of dangerous medical waste, chemotherapy patients treated with any of more than two dozen different chemotherapy drugs who return home after outpatient treatment can inadvertently but easily expose others to genotoxic contamination through seemingly benign occurrences such as urine splashed on a bathroom floor, clean up after an episode of vomiting, or the handling of bed sheets or a bedpan for a patient unable to use a bathroom.

The WHO report address what many in the field of chemotherapy-based treatment have long acknowledged as a dangerous "blind spot."
The human body can only destroy a portion of these genotoxic drugs. The rest passes out of the patient in urine, feces, vomit, or even sweat. The waste will still have enough dangerous drug to kill developing cells and/or cause mutations in vulnerable members of our population, especially fetuses and babies.

The WHO has done a great public service by stepping up and publicly declaring what many of us in the field have long known — this is a serious risk.

WHO core principles "require that everyone associated with financing and supporting health-care activities should provide for the costs of managing health-care waste. This is the duty of care. Manufactures also share a responsibility to take waste management into account in the development and sale of their products and services."

The WHO goes on to identify those who have a special responsibility to ensure safe collection, containment and disposal of these wastes, placing much of that responsibility with the chief pharmacist. "The chief pharmacist also has the special responsibility of ensuring that genotoxic products are used safely, and that genotoxic waste is managed safely," according to the WHO.

Jim Mullowney is the founder and CEO of Newport-based Pharma-Cycle Inc

Media Contact: Jim Mullowney, Pharma-Cycle, Inc., 617-755-0883, jmullowney@pharma-cycle.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Pharma-Cycle, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Big Pharma to Come Together at ChemOutsourcing 2013 in Long Branch, New Jersey, Sept 16-19
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. ChemOutsourcing Announces 100 CMO and CRO Exhibitors for September 2013 Show in Long Branch, New Jersey
4. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
5. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
6. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
7. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
8. Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
9. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
10. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited to announce ... Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on the face, ... ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of the body ...
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... ... Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, ... (war) trauma, to encourage inner healing of memories and achieve forgiveness, through a ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Pot Valet is ... service growing to every city in the state, and soon, every state in the ... their need to visit a cannabis dispensary altogether. , According to Pot ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/17/2017)... Seattle, WA and Lighthouse Point, FL (PRWEB) , ... ... ... Seattle-based healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology ... that examined patient care data to quantify the dollar amount of attributable savings ...
Breaking Medicine News(10 mins):